Comparison
Magnesium L-Threonate vs Rapamycin
Magnesium L-Threonate
MIT-developed magnesium that crosses the blood-brain barrier. Shown to enhance synaptic density and reduce 'brain age'.
Rapamycin
mTOR inhibitor approved for immunosuppression after organ transplant. Studied off-label for longevity at low intermittent doses.
| Field | Magnesium L-Threonate | Rapamycin |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 1000–2000mg | 5–10mg |
| Half-life | 6h | — |
| Onset | — | — |
| Evidence | EVIDENCEB | EVIDENCEA |
| Safety | ●●●●● | ●●○○○ |
| Legal (US) | USOTC | USRx |
| PubMed refs | 90 | 36000 |
The comparison in plain English
Auto-generated from dataMagnesium L-Threonate and Rapamycin are both in the neuroprotective category respectively. Magnesium L-Threonate MIT-developed magnesium that crosses the blood-brain barrier. Rapamycin mTOR inhibitor approved for immunosuppression after organ transplant.
Bottom line
Magnesium L-Threonate (evidence B, safety 5/5) has a stronger evidence base than Rapamycin (evidence A, safety 2/5). Magnesium L-Threonate has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Magnesium L-Threonate if
Magnesium L-Threonate is the better fit when your goal aligns with its mechanism (L-threonate is a sugar-acid carrier that uniquely enables magnesium to cross the blood-brain barrier in meaningful quantities — most oral magnesium forms (oxide, citrate, glycinate) raise serum magnesium but not central magnesium) and the dose range (1000–2000mg) suits your protocol. Half-life is 6h.
Choose Rapamycin if
Rapamycin is the better fit when your goal aligns with its mechanism (Selective inhibitor of mTORC1 (mechanistic target of rapamycin complex 1), reducing protein synthesis and inducing autophagy) and the dose range (5–10mg) suits your protocol. Half-life is —h.